Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6754)
All Articles published online
|
Publishing Process of This Article
|
Jul 26, 2021 (publication date) through Jun 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021; 9(21): 5769-5781 [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i21/5769.htm |
| Number | Citing Articles |
| 1 |
Jia-Rui Zheng, Zi-Long Wang, Bo Feng. Hepatitis B functional cure and immune response. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1075916
|
| 2 |
Galina I. Gridneva, Boris S. Belov, Evgeniia S. Aronova. Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review. Terapevticheskii arkhiv 2024; 96(5): 523 doi: 10.26442/00403660.2024.05.202707
|
| 3 |
Sara Lacerda Pereira, Raquel Duro, António Sarmento. Late Hepatitis B reactivation after treatment with rituximab. IDCases 2022; 27: e01393 doi: 10.1016/j.idcr.2022.e01393
|
| 4 |
Caterina Sagnelli, Antonello Sica, Massimiliano Creta, Alessandra Borsetti, Massimo Ciccozzi, Evangelista Sagnelli. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022; 11(5): 567 doi: 10.3390/pathogens11050567
|
| 5 |
Serena Zaltron, Anna Cambianica, Marco Di Gregorio, Cosimo Colangelo, Samuele Storti, Giorgio Tiecco, Francesco Castelli, Eugenia Quiros-Roldan. Case report: An occult hepatitis B virus infection reactivation in an HIV/HCV coinfected patient during an immune reconstitution inflammatory syndrome. Frontiers in Cellular and Infection Microbiology 2023; 13 doi: 10.3389/fcimb.2023.1143346
|
| 6 |
Tânia Lourenço, Nuno Vale. Entecavir: A Review and Considerations for Its Application in Oncology. Pharmaceuticals 2023; 16(11): 1603 doi: 10.3390/ph16111603
|
| 7 |
Chunyan Yuan, Jing Peng, Renxiang Xia, Jian He, Tianji Qiu, Yunqing Yao. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.865124
|
| 8 |
Adeniyi Abraham Adesola, Matei-Alexandru Cozma, Yong-Feng Chen, Bahadar Singh Srichawla, Mihnea-Alexandru Găman. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. World Journal of Hepatology 2023; 15(11): 1188-1195 doi: 10.4254/wjh.v15.i11.1188
Abstract(274) |
Core Tip(212) |
Full Article(HTML)(1168)
|
Full Article with Cover (PDF)-1278K(58)
|
Full Article (Word)-185K(25)
|
Audio-1002K(4)
|
Peer-Review Report-190K(29)
|
Answering Reviewers-264K(32)
|
Full Article (PDF)-482K(98)
|
Full Article (XML)-81K(54)
|
Times Cited (0)
|
Total Visits (3178)
|
Open
|
| 9 |
Jiajia Hu, Jie Zhao, Chunyan Wang, Mei Jia, Ming Su, Shanshan Li. Epstein–Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation. Annals of Hematology 2023; 102(12): 3593 doi: 10.1007/s00277-023-05492-z
|
| 10 |
Shahrzad Shoraka, Seyed Reza Mohebbi, Seyed Masoud Hosseini, Amir Ghaemi, Mohammad Reza Zali. SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection. Journal of Clinical Virology Plus 2023; 3(4): 100167 doi: 10.1016/j.jcvp.2023.100167
|
| 11 |
Zahra Dossaji, Lubaba Haque, Adam Khattak, Mark Hsu, Robert Gish. A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators. Current Hepatology Reports 2024; 23(2): 253 doi: 10.1007/s11901-024-00662-7
|